Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SGK1 | O00141 | 20/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | SGK3 | Q96BR1 | 1/20 | 0.62 |
| ▸ | SGK2 | Q9HBY8 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22943349 | 0.85 | SGK1 (0.67) | SGK1 | |
| SCHEMBL22944013 | 0.84 | SGK1 (0.66) | SGK1CYP3A4SGK3SGK2 | |
| SCHEMBL22944242 | 0.82 | SGK1 (0.72) | SGK1CYP3A4SGK3SGK2 | |
| SCHEMBL22943360 | 0.81 | SGK1 (0.62) | SGK1CYP3A4SGK3SGK2 | |
| SCHEMBL16052469 | 0.78 | SGK1 (1.00) | SGK1 | |
| SCHEMBL14775140 | 0.77 | SGK1 (0.75) | SGK1CYP3A4SGK3SGK2 | |
| SCHEMBL14774958 | 0.77 | SGK1 (0.75) | SGK1CYP3A4SGK3SGK2 | |
| SCHEMBL14775363 | 0.77 | SGK1 (1.00) | SGK1CYP3A4SGK3SGK2 | |
| Hydrochloric Acid SCHEMBL14811999 | 0.77 | SGK1 (0.73) | SGK1CYP3A4SGK3SGK2 | |
| SCHEMBL31511474 | 0.77 | SGK1 (1.00) | SGK1CYP3A4SGK3SGK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11236083-B2 | Compounds and pharmaceutical compositions for modulating SGK activity, and methods thereof | Orimos Therapeutics Co., Ltd. (CN) | 2022-02-01 | — | — | US | disclosed |
| US-20210032239-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR MODULATING SGK ACTIVITY, AND METHODS THEREOF | Orimos Therapeutics Co., Ltd. (CN) | 2021-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11236083-B2 | Compounds and pharmaceutical compositions for modulating SGK activity, and methods thereof | SGK1, SGK2, SGK3 | SGK1 1/4885CYP3A4 2482/4885SGK3 3/4885 |
| US-20210032239-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR MODULATING SGK ACTIVITY, AND METHODS THEREOF | SGK1, SGK2, SGK3 | SGK1 1/4885CYP3A4 3863/4885SGK3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.